MX2019009304A - Tratamiento para el cancer. - Google Patents

Tratamiento para el cancer.

Info

Publication number
MX2019009304A
MX2019009304A MX2019009304A MX2019009304A MX2019009304A MX 2019009304 A MX2019009304 A MX 2019009304A MX 2019009304 A MX2019009304 A MX 2019009304A MX 2019009304 A MX2019009304 A MX 2019009304A MX 2019009304 A MX2019009304 A MX 2019009304A
Authority
MX
Mexico
Prior art keywords
cancer treatment
cancer
treatment
erdafitinib
provides
Prior art date
Application number
MX2019009304A
Other languages
English (en)
Inventor
STUYCKENS Kim
Jose PEREZ RUIXO Juan
Marie Z De Porre Peter
Narayan Avadhani Anjali
LORIOT Yohann
O Siefker-Radtke Arlene
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61094531&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019009304(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Priority claimed from PCT/EP2018/052694 external-priority patent/WO2018141921A1/en
Publication of MX2019009304A publication Critical patent/MX2019009304A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

La presente invencion proporciona un metodo para el tratamiento del cancer con erdafitinib.
MX2019009304A 2017-02-06 2018-02-02 Tratamiento para el cancer. MX2019009304A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762455211P 2017-02-06 2017-02-06
EP17209098 2017-12-20
PCT/EP2018/052694 WO2018141921A1 (en) 2017-02-06 2018-02-02 Cancer treatment

Publications (1)

Publication Number Publication Date
MX2019009304A true MX2019009304A (es) 2019-09-19

Family

ID=61094531

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019009304A MX2019009304A (es) 2017-02-06 2018-02-02 Tratamiento para el cancer.
MX2022007955A MX2022007955A (es) 2017-02-06 2019-08-05 Regimenes de dosificacion de erdafitinib.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022007955A MX2022007955A (es) 2017-02-06 2019-08-05 Regimenes de dosificacion de erdafitinib.

Country Status (24)

Country Link
US (2) US11077106B2 (es)
EP (2) EP3576740B1 (es)
JP (2) JP2020505425A (es)
KR (1) KR20190110581A (es)
CN (1) CN110198716A (es)
AU (2) AU2018216969B2 (es)
BR (1) BR112019016043A2 (es)
CA (1) CA3049737A1 (es)
DK (1) DK3576740T3 (es)
ES (1) ES2953005T3 (es)
FI (1) FI3576740T3 (es)
HR (1) HRP20230697T1 (es)
HU (1) HUE062453T2 (es)
IL (1) IL268463A (es)
JO (1) JOP20190190A1 (es)
LT (1) LT3576740T (es)
MX (2) MX2019009304A (es)
PH (1) PH12019501885A1 (es)
PL (1) PL3576740T3 (es)
RS (1) RS64778B1 (es)
SG (2) SG10202105110VA (es)
SI (1) SI3576740T1 (es)
TW (1) TW202402290A (es)
UA (1) UA126336C2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200208224A1 (en) * 2014-09-26 2020-07-02 Janssen Pharmaceutica Nv Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor
WO2021201201A1 (ja) * 2020-04-03 2021-10-07 インタープロテイン株式会社 新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の予防または治療剤および医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) * 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer

Also Published As

Publication number Publication date
JOP20190190A1 (ar) 2019-08-04
PL3576740T3 (pl) 2023-09-11
EP4286005A2 (en) 2023-12-06
HUE062453T2 (hu) 2023-11-28
JP2020505425A (ja) 2020-02-20
EP4286005A3 (en) 2024-03-06
SG10202105110VA (en) 2021-06-29
CA3049737A1 (en) 2018-08-09
JP2023022190A (ja) 2023-02-14
AU2018216969B2 (en) 2024-04-11
ES2953005T3 (es) 2023-11-07
EP3576740A1 (en) 2019-12-11
PH12019501885A1 (en) 2020-06-29
KR20190110581A (ko) 2019-09-30
BR112019016043A2 (pt) 2020-03-31
AU2024201871A1 (en) 2024-04-11
AU2018216969A1 (en) 2019-07-25
IL268463A (en) 2019-09-26
TW202402290A (zh) 2024-01-16
LT3576740T (lt) 2023-08-10
SI3576740T1 (sl) 2023-10-30
SG11201907199QA (en) 2019-09-27
FI3576740T3 (fi) 2023-08-31
US20200022976A1 (en) 2020-01-23
HRP20230697T1 (hr) 2023-10-13
DK3576740T3 (da) 2023-07-24
US11077106B2 (en) 2021-08-03
CN110198716A (zh) 2019-09-03
US20220110935A1 (en) 2022-04-14
RS64778B1 (sr) 2023-11-30
MX2022007955A (es) 2022-07-27
UA126336C2 (uk) 2022-09-21
EP3576740B1 (en) 2023-06-14

Similar Documents

Publication Publication Date Title
ZA201906111B (en) Cyclic di-nucleotides compounds for the treatment of cancer
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
EP3641770A4 (en) METHOD OF TREATMENT OF CANCER
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
MX2017014163A (es) Moduladores de k-ras.
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
EA201991818A1 (ru) Лечение рака
WO2018136617A3 (en) Bacteria for treating cancer
MX2020003770A (es) Terapias de combinacion para tratar cancer.
MX2017001490A (es) Combinaciones de farmacos para tratar mieloma multiple.
PH12017501151A1 (en) Processes for the preparation of a diarylthiohydantoin compound
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
MX2020006297A (es) Variantes de cd19.
MX2020007742A (es) Procesos para preparar fluorocetolidos.
PH12017501864A1 (en) Compositions and methods for treating autism
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
MX2021009670A (es) Tratamiento para el cancer.
MX2018000694A (es) Tratamiento del prurito.
MX2020012964A (es) Metodos para el tratamiento de cancer de vejiga.
MX2019009199A (es) Composiciones y métodos para modular ppp2r1a.